AU2021262521A1 - Betacoronavirus prophylaxis and therapy - Google Patents

Betacoronavirus prophylaxis and therapy Download PDF

Info

Publication number
AU2021262521A1
AU2021262521A1 AU2021262521A AU2021262521A AU2021262521A1 AU 2021262521 A1 AU2021262521 A1 AU 2021262521A1 AU 2021262521 A AU2021262521 A AU 2021262521A AU 2021262521 A AU2021262521 A AU 2021262521A AU 2021262521 A1 AU2021262521 A1 AU 2021262521A1
Authority
AU
Australia
Prior art keywords
seq
vaccine according
unit
protein
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021262521A
Other languages
English (en)
Inventor
Agnete Brunsvik Fredriksen
Gunnstein NORHEIM
Karoline SCHJETNE
Monika Sekelja
Elisabeth STUBSRUD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nykode Therapeutics ASA
Original Assignee
Nykode Therapeutics ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA filed Critical Nykode Therapeutics ASA
Publication of AU2021262521A1 publication Critical patent/AU2021262521A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021262521A 2020-05-01 2021-05-03 Betacoronavirus prophylaxis and therapy Pending AU2021262521A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
DKPA202070282 2020-05-01
DKPA202070282 2020-05-01
DKPA202070293 2020-05-06
DKPA202070293 2020-05-06
DKPA202070735 2020-11-05
DKPA202070735 2020-11-05
DKPA202070820 2020-12-08
DKPA202070820 2020-12-08
DKPA202170069 2021-02-15
DKPA202170069 2021-02-15
PCT/EP2021/061602 WO2021219897A1 (en) 2020-05-01 2021-05-03 Betacoronavirus prophylaxis and therapy

Publications (1)

Publication Number Publication Date
AU2021262521A1 true AU2021262521A1 (en) 2022-12-08

Family

ID=75870604

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021262521A Pending AU2021262521A1 (en) 2020-05-01 2021-05-03 Betacoronavirus prophylaxis and therapy

Country Status (11)

Country Link
US (1) US20230165952A1 (https=)
EP (1) EP4143210A1 (https=)
JP (1) JP2023524054A (https=)
KR (1) KR20230005962A (https=)
CN (1) CN116096735A (https=)
AU (1) AU2021262521A1 (https=)
BR (1) BR112022021905A2 (https=)
CA (1) CA3176527A1 (https=)
IL (1) IL297621A (https=)
MX (1) MX2022013661A (https=)
WO (1) WO2021219897A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
CN112028978B (zh) * 2020-09-07 2023-06-16 重庆医科大学 新冠病毒特异性cd8+t细胞表位肽及其应用
BR112023000666A2 (pt) 2021-04-12 2023-10-24 Academia Sinica Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
BR112023023260A2 (pt) 2021-05-10 2024-01-30 Nykode Therapeutics ASA Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica
JP2024518463A (ja) 2021-05-10 2024-05-01 ナイコード セラピューティクス アルメン アクスイェ セルスカプ 構築物及び免疫阻害化合物の共発現
TW202334429A (zh) * 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN113801209B (zh) * 2021-11-16 2022-02-11 浙江普康生物技术股份有限公司 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法
GB202201765D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Methods
CN114832099B (zh) * 2022-04-08 2023-11-28 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂
CN114907452B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽
US20260007729A1 (en) * 2022-08-17 2026-01-08 IMMUNEO Therapeutics GmbH Immunization against viral infections disease(s)
WO2024038157A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against coronavirus
LU102995B1 (en) * 2022-08-17 2024-02-19 PMCR GmbH Immunization against coronavirus
WO2024044747A2 (en) * 2022-08-25 2024-02-29 University Of Florida Research Foundation, Inc. Immunogenic composition and uses thereof
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2024155907A2 (en) * 2023-01-20 2024-07-25 Duke University Epitope-scaffold immunogens for pancoronavirus vaccines
WO2024210175A1 (ja) * 2023-04-07 2024-10-10 国立大学法人大阪大学 濾胞性ヘルパーＴ細胞誘導性ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質の部分ペプチド
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (en) 2023-05-17 2024-11-21 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof
CN119143850A (zh) * 2024-08-20 2024-12-17 复旦大学 广谱抑制流感病毒的多肽及在预防和/或治疗流感病毒感染中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531204T3 (es) 2003-02-25 2015-03-11 Vaccibody As Anticuerpo modificado
JP2013532971A (ja) * 2010-06-25 2013-08-22 バッシボディ アクスイェ セルスカプ ホモ二量体タンパク質コンストラクト
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
BR112014015016B1 (pt) 2011-12-21 2023-10-03 Nykode Therapeutics ASA Proteína homodimérica de duas cadeias de aminoácidos idênticas,cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica,célula hospedeira, método de preparação de uma proteína homodimérica, método de preparação de uma vacina e vacina
IL260030B2 (en) * 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
EP3678699A1 (en) * 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
WO2020176797A1 (en) 2019-02-27 2020-09-03 Nektar Therapeutics Immunotherapeutic combination for treating cancer
LT3972987T (lt) * 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
WO2021216954A1 (en) * 2020-04-23 2021-10-28 Alpha Beta Holdings, Llc Compositions and methods for treating or preventing virus infection

Also Published As

Publication number Publication date
KR20230005962A (ko) 2023-01-10
CA3176527A1 (en) 2021-11-04
IL297621A (en) 2022-12-01
WO2021219897A1 (en) 2021-11-04
CN116096735A (zh) 2023-05-09
BR112022021905A2 (pt) 2022-12-13
JP2023524054A (ja) 2023-06-08
MX2022013661A (es) 2022-11-30
US20230165952A1 (en) 2023-06-01
EP4143210A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
US20230165952A1 (en) Betacoronavirus prophylaxis and therapy
US12234264B2 (en) Stabilized soluble pre-fusion RSV F proteins
CA1340896C (en) Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins
AU2011268934B2 (en) Homodimeric protein constructs
CN115850506B (zh) 一种cd4辅助性t细胞表位融合肽及其疫苗
US20220054625A1 (en) Immunogenic composition
US20250109175A1 (en) Recombinant gp120 protein with v1-loop deletion
CN120475991A (zh) 鼻病毒mRNA疫苗
WO2015175361A1 (en) Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development
Phatarphekar et al. RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice
US20250339509A1 (en) Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
CN118076646A (zh) 一种可诱导广谱中和活性重组多组分新冠病毒三聚体蛋白疫苗的制备及应用
WO2022238363A1 (en) Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
Cano The multi-epitope polypeptide approach in HIV-1 vaccine development
WO2023018817A1 (en) Truncated influenza neuraminidase and methods of using the same
RU2848314C1 (ru) Профилактика и лечение бетакоронавируса
RU2811991C2 (ru) Субъединичная вакцина для лечения или предотвращения инфекции дыхательных путей
US20260007734A1 (en) Immunogenic compositions for the prevention of influenza a
KR20240110821A (ko) SARS-CoV-2로 인한 질병의 예방적 및 치료적 처치에 사용하기 위한 면역원성 작제물 및 백신
CN118742321A (zh) 用于预防性和治疗性治疗由SARS-CoV-2引起的疾病的免疫原性构建体和疫苗
CN119161427A (zh) 一种SARS-CoV-2小广谱疫苗免疫原性蛋白及其应用
CN121574211A (zh) 一种新型冠状病毒重组亚单位抗原及其制备方法和在疫苗中的应用